PPP1R15B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL29447252	1.00	1/20
SCHEMBL30872248	1.00	1/20
Hydrochloric Acid (SCHEMBL5703102)	0.97	1/20
Acetic Acid (SCHEMBL29736263)	0.82	1/20
SCHEMBL15884162	0.74	1/20
SCHEMBL29445212	0.74	1/20
Guanabenz (SCHEMBL15390)	0.66	1/20
Guanabenz (SCHEMBL219392)	0.66	1/20
Hydrochloric Acid (SCHEMBL5703211)	0.63	1/20
SCHEMBL534016	0.59	1/20
SCHEMBL534017	0.59	1/20
SCHEMBL2161103	0.59	1/20
SCHEMBL6847216	0.59	1/20
SCHEMBL30275282	0.59	1/20
SCHEMBL32680261	0.59	1/20
SCHEMBL5316715	0.57	1/20
SCHEMBL28482894	0.56	1/20
SCHEMBL17560810	0.56	1/20
SCHEMBL17560814	0.56	1/20
Guanabenz (SCHEMBL3054917)	0.55	1/20

Clinical trials — most relevant to PPP1R15B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis	PHASE4	COMPLETED
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	PHASE2	COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	PHASE1/PHASE2	COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects	PHASE1	COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
Immune Signature of Palmoplantar Pustulosis	nan	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Studying Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia Previously Enrolled on Clinical Trial POG-9421	nan	COMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Studies of the Tumour Suppressor Gene PTEN - Endometrial Cancer	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
Studying Phosphorus Metabolism	nan	COMPLETED
Effect of Supplementing a Mixed Macronutrient Beverage With Graded Doses of Leucine on Myofibrillar Protein Synthesis	nan	COMPLETED
Evaluating Changes in Skeletal Muscle Proteins Following Resistance Exercise and Single-Leg Disuse	nan	COMPLETED
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PPP1R15B binder may also engage these)

Protein	Name	Similarity
Q8BFW3	—	1.000	Q8BFW3 →
Q9NWN3	—	0.987	Q9NWN3 →
Q3USH1	—	0.982	Q3USH1 →
Q80XI1	—	0.982	Q80XI1 →
Q8C963	—	0.982	Q8C963 →
Q6ZSG2	—	0.981	Q6ZSG2 →
Q9NYF0	—	0.981	Q9NYF0 →
Q5U5Q9	—	0.981	Q5U5Q9 →
Q6PJW8	—	0.981	Q6PJW8 →
A0P8Z5	—	0.981	A0P8Z5 →
Q5PQK4	—	0.981	Q5PQK4 →
Q8CBC4	—	0.980	Q8CBC4 →
Q96RL1	—	0.979	Q96RL1 →
Q8BP99	—	0.978	Q8BP99 →
A6NNL0	—	0.978	A6NNL0 →
Q5JXC2	—	0.978	Q5JXC2 →
Q80W88	—	0.977	Q80W88 →
Q7TN08	—	0.977	Q7TN08 →
Q66JV7	—	0.977	Q66JV7 →
O75410	—	0.977	O75410 →
Q7TT79	—	0.977	Q7TT79 →
B1AL46	—	0.977	B1AL46 →
C9JSJ3	—	0.977	C9JSJ3 →
B1ASB6	—	0.977	B1ASB6 →
Q5RCQ2	—	0.977	Q5RCQ2 →
Q6ZNL6	—	0.977	Q6ZNL6 →
A0A5K7RLP0	—	0.976	A0A5K7RLP0 →
Q60829	—	0.976	Q60829 →
Q9C0C6	—	0.976	Q9C0C6 →
Q76N32	—	0.976	Q76N32 →